Search for: "Amgen Inc. v. Sanofi" Results 41 - 60 of 110
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
22 May 2024, 10:00 pm
Its decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme Court’s reasoning in Amgen Inc. v. [read post]
6 Oct 2017, 2:34 pm by Aaron Barkoff
Finding for Sanofi, the court held the sentence to be improper, relying heavily on its decision in Centocor Ortho Biotech, Inc. v. [read post]
6 Oct 2017, 2:34 pm by Aaron Barkoff
Finding for Sanofi, the court held the sentence to be improper, relying heavily on its decision in Centocor Ortho Biotech, Inc. v. [read post]
8 May 2021, 10:26 pm by Patent Docs
The panel will cover recent developments in the Hatch-Waxman and BPCIA litigation and legislation, in particular, the Federal Circuit decisions in Amgen Inc. v. [read post]
28 Feb 2018, 9:35 pm by Patent Docs
The memorandum, entitled "Clarification of Written Description Guidance For Claims Drawn to Antibodies and Status of 2008 Training Materials," is divided into three sections, which address the Federal Circuit's recent decision in Amgen Inc. v. [read post]
1 Jul 2022, 10:02 am by Dennis Crouch
The current most-likely big case is Amgen Inc., et al. v. [read post]
27 Apr 2023, 11:51 am by Dennis Crouch
The pending Supreme Court case of Amgen Inc. v. [read post]